Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts

Leukemia and Lymphoma

Volumn 54, Issue 10, 2013, Pages 2255-2262

  Hilchie, Ashley L ^a   Conrad, David M ^b   Power Coombs, Melanie R ^a   Zemlak, Tyler ^a   Doucette, Carolyn D ^a   Liwski, Robert S ^a,b   Hoskin, David W ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Cytolysis; DNA fragmentation; Host defense peptide; Plasma cell myeloma

Indexed keywords

NRC 03; NRC 07; PLEUROCIDIN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING COMPETITION; CELL GROWTH; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYSIS; MEMBRANE DAMAGE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA FRAGMENTATION; FEMALE; FISH PROTEINS; HUMANS; MICE; MULTIPLE MYELOMA; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884478109     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.770847     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
4. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526.
5. Bulet P, Stocklin R, Menin L. A nti-microbial peptides: From invertebrates to vertebrates. Immunol Rev 2004; 198: 169-184.
6. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.
7. Yeung AT, Gellatly SL, Hancock REW. Multifunctional cationic host defence peptides and their clinical application. Cell Mol Life Sci 2011; 68: 2161-2176.
8. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochem Biophys Acta 2008; 1778: 357-375.
9. Hilchie AL, Doucette CD, Pinto DM, et al. Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts. Breast Cancer Res 2011; 13: R102.
10. Mader JS, Salsman J, Conrad DM, et al. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther 2005; 4: 612-624.
11. Zachowski A. Phospholipids in animal eukaryotic membranes: Transverse asymmetry and movement. Biochem J 1993; 294: 1-14.
12. Utsugi T, Schroit AJ, Connor J, et al. Elevated expression of phosphatidylserine in the outer membrane leafl et of human tumor cells and recognition by activated human blood monocytes. Cancer Res 1991; 51: 3062-3066.
13. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: The mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010; 29: 2893-2904.
14. van Beek WP, Smets LA, Emmelot P. Increased sialic acid density in surface glycoprotein of transformed and malignant cells-a general phenomenon? Cancer Res 1973; 33: 2913-2922.
15. Koo CY, Sen YP, Bay BH, et al. Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Pat Anticancer Drug Discov 2008; 3: 151-158.
16. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-1132.
17. Vaz Gomes A, de Waal A, Berden JA, et al. Electric potentiation, cooperativity, and synergism of magainin peptides in protein-free liposomes. Biochemistry 1993; 32: 5365-5372.
18. Sok M, Sentjurc M, Schara M. Membrane fluidity characteristics of human lung cancer. Cancer Lett 1999; 139: 215-220.
19. Kim S, Kim SS, Bang YJ, et al. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 2003; 24: 945-953.
20. Hui L, Leung K, Chen HM. The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res 2002; 22: 2811-2816.
21. Patrzykat A, Gallant JW, Seo JK, et al. Novel antimicrobial peptides derived from fl atfish genes. Antimicrob Agents Chemother 2003; 47: 2464-2470.
22. Furlong SJ, Mader JS, Hoskin DW. Bovine lactoferricin induces caspase-independent apoptosis in human B-lymphoma cells and extends the survival of immune-deficient mice bearing B-lymphoma xenografts. Exp Mol Pathol 2010; 88: 371-375.
23. Ausbacher D, Svineng G, Hansen T, et al. Anticancer mechanisms of action of two small amphipathic (2,2)-amino acid derivatives derived from antimicrobial peptides. Biochim Biophys Acta 2012; 1818: 2917-2925.
24. Morash MG, Douglas SE, Robotham A, et al. The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents. Dis Model Mech 2011; 4: 622-633.
25. Saint N, Cadiou H, Bessin Y, et al. A ntibacterial peptide pleurocidin forms ion channels in planar lipid bilayers. Biochim Biophys Acta 2002; 1564: 359-364.
26. Chen X, X u X, Hong S, et al. RGD-tachyplesin inhibits tumor growth. Cancer Res 2001; 61: 2434-2438.
27. Berge G, Eliassen LT, Camilio KA, et al. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol Immunother 2010; 59: 1285-1294.
28. Mader JS, Ewen C, Hancock REW, et al. The human cathelicidin, LL-37, induces granzyme-mediated apoptosis in regulatory T cells. J Immunother 2011; 34: 229-235.